Research Agreement with University of North Carolina
Filed with ASX · · 2 pages · English
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Reinstatement to Official Quotation
- Prospectus
- Arovella $15m Placement to fund Phase 1
- Voluntary Suspension
- Trading Halt
Later from Arovella Therapeutics
- S&P DJI Announces March 2025 Quarterly Rebalance
- Appendix 4E and Annual Report
- S&P DJI Announces September 2025 Quarterly Rebalance
- Arovella receives R&D tax rebate of $3.21 million
- CLDN18.2 CAR-T cells eliminate pancreatic cancer cells
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics